InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,099.96
(
1.02%
)
US TECH 100
17,244.80
(
1.57%
)
Dow Jones
38,239.66
(
0.40%
)
Brent Oil
88.17
(
0.00%
)
Bitcoin
63,621.93
(
0.33%
)
Post# of 251624
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119503
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 193119

Friday, 11/13/2015 1:44:56 PM

Friday, November 13, 2015 1:44:56 PM

Post# of 251624
MDCO/EGRX/PFE—CAFC agrees to en banc rehearing of Angiomax patent case:

https://twitter.com/danravicher/status/665236027972435968

Please see #msg-115121863 for background.

The en banc rehearing is potentially positive for EGRX because it has a ready-to-use liquid formulation of Angiomax (PDUFA date 3/20/6) that MDCO now has an enhanced motivation to license. (The MDCO patent in question expires in 2029.)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up